Genomic Health Inc. (GHDX)

Oncology Corporate Profile

Stock Performance

31.2400
0.2600

3 Month Stock History Chart

HQ Location

301 Penobscot Drive
Redwood City, CA 94063

Company Description

Genomic Health is a life science company that conducts sophisticated genomic research to develop clinically validated molecular diagnostics, which provide individualized information on the likelihood of disease recurrence and response to certain types of therapy. These diagnostic technologies generate information that healthcare providers and patients can use in making treatment decisions.

Website: http://www.genomichealth.com

Brand Generic Indication
Oncotype DX®N/AThe Oncotype DX® Breast Recurrence Score™ was developed to meet this clinical challenge. This unique genomic test is the only genomic test validated to predict adjuvant therapy benefit in patients with ER+, HER2-negative, early-stage invasive breast cancer; Provides an individualized and quantitative risk assessment that identifies the patient’s 10-year risk of distant recurrence; Delivers information beyond clinical and pathologic features; Is supported by data from studies with over 9,000 patients; Is included in major clinical guidelines for chemotherapy decision-making; Has potentially helped thousands of patients around the globe avoid chemotherapy and its side effects.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Breast Cancer Genomic Signature TestdiagnosticsBreast cancer BiomarkerDevelopment
Colorectal Cancer Genomic Signature TestdiagnosticsColorectal cancer BiomarkerDevelopment
Melanoma Genomic Signature TestdiagnosticsMelanoma BiomarkerDevelopment
NSCLC Genomic Signature TestdiagnosticsNon Small Cell Lung Cancer (NSCLC) BiomarkerDevelopment
Prostate Cancer Genomic Signature TestdiagnosticsProstate cancer BiomarkerDevelopment
Renal Cancer Genomic Signature TestdiagnosticsRenal cell carcinoma (RCC) BiomarkerDevelopment

View additional information on product candidates here »

Source: http://www.genomichealth.com

Recent News Headlines

Inivata and N-of-One Partner to Provide Personalized Genomic Interpretation and Clinical Trial Matching for Cancer Patients

11/3/2016 04:45 pm

(Inivata) Nov 3, 2016 - Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, and N-of-One, Inc., a precision medicine oncology decision support company, are pleased to announce a new partnership to support analysis of patient cases for Inivata’s InVision® liquid biopsy product line.

Genomic Health Announces Positive Topline Clinical Validation Study Results Demonstrating Oncotype DX® Prostate Cancer Test Predicts Risk of Metastasis and Mortality

11/2/2016 04:12 pm

(Yahoo! Finance) Nov 1, 2016 - Genomic Health, Inc. today announced topline results from a large clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score™.

NantHealth Announces Immunotherapy Clinical Trials in the Mid-Atlantic, First Whole Genomics Supercomputing Medical Reasoning Engine Helps Oncologists Make Informed Treatment Decisions for Cancer Patients

10/27/2016 04:50 pm

(Yahoo! Finance) Oct 26, 2016 - Panel discussion and press conference with Dr. Patrick Soon-Shiong, Founder and CEO of NantHealth, Inc. (NH), a leading next-generation, evidence-based, personalized healthcare company, and esteemed leadership of Horizon Blue Cross Blue Shield of New Jersey who will cover GPS Cancer tests to advance molecular science for its members enrolled in investigational studies for key cancer types—non-small cell lung cancer, breast cancer, colon cancer, and cancer of unknown primary—across leading health systems in the mid-Atlantic

New Data Show that Use of Percepta® Bronchial Genomic Classifier Reduces Surgeries and Other Costly Procedures in Lung Cancer Screening and Diagnosis

10/27/2016 04:44 pm

(Yahoo! Finance) Oct 26, 2016 - Veracyte, Inc. today announced new data from a prospective, multicenter clinical utility study showing that use of the Percepta Bronchial Genomic Classifier to resolve inconclusive diagnostic results in patients undergoing evaluation for suspected lung cancer led to a significant reduction in surgeries and other costly, invasive procedures.

Genomic Health Presents Robust Analytical Validation Study Results of Oncotype SEQ(TM) Liquid Biopsy Mutation Panel

10/11/2016 04:56 pm

(4-traders) Oct 11, 2016 - Genomic Health, Inc. today announced results from its successfully completed analytical validation study of Oncotype SEQ™ Liquid Select, which demonstrated that this liquid biopsy mutation panel is highly sensitive, specific and reproducible.

GenomeDx Launches Expanded GRID Tumor Profiling to Provide Enhanced Genomic Understanding of Patients' Prostate Cancer

10/3/2016 05:06 pm

(GenomeDx) Sept 29, 2016 - GenomeDx Biosciences today announced that it has launched an expanded version of its Decipher GRID® Tumor RNA Expression Profile, a report generated for prostate tumors profiled with a Decipher Prostate Cancer Classifier test.

Color Genomics Raises $45 Million to Expand Genetic Testing

9/27/2016 03:45 pm

(Bloomberg) Sept 27, 2016 - Color Genomics Inc., the three-year-old startup aiming to democratize genetic testing, sealed $45 million in funding as it seeks to make its tests for cancer more affordable and accessible, the company announced Tuesday.

Biotheranostics & Syapse Collaborate to Integrate Genomics-Based Molecular Diagnostics for Cancer into the Syapse Precision Medicine Platform

9/26/2016 04:20 pm

(Morningstar) Sept 22, 2016 - Breast Cancer Index & CancerTYPE ID tests provide patient-specific information to aid in treatment decisions with the goal of improving outcomes.

Syros Announces First Patient Enrolled in Phase 2 Clinical Trial of SY-1425 in Genomically Defined Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

9/22/2016 03:54 pm

(Syros Pharmaceuticals) Sept 22, 2016 - Syros Pharmaceuticals announced today that the first patient has been dosed in the Phase 2 clinical trial of its lead drug candidate, SY-1425, a first-in-class selective retinoic acid receptor alpha (RARa) agonist.

GenomeDx Adds Multiple Leading Cancer Centers to Its Proprietary Genomics Resource Information Database Platform (Decipher GRID)

9/14/2016 04:44 pm

(TheStreet) Sept 13, 2016 - GenomeDx Biosciences today announced that it has expanded access to its Decipher Genomics Resource Information Database (Decipher GRID ®) to a new group of leading cancer centers, allowing them to join the existing Decipher GRID network.

Multiple Myeloma Research Foundation (MMRF) and University of Michigan Team up on a New Molecular Profiling Initiative to Speed Genomic Sequencing Results to Patients

8/8/2016 04:24 pm

(Digital Journal) Aug 5, 2016 - The Multiple Myeloma Research Foundation (MMRF), together with the University of Michigan, today announced a collaboration to perform clinical-grade (CLIA) genomic sequencing on hundreds of relapsed and refractory multiple myeloma (MM) patients over a two year period.

Cure Forward Selects Personal Genome Diagnostics as a Provider of Genomic Data to Cancer Patients Using Its Platform to Access Precision Medicine Treatment Options

8/2/2016 04:20 pm

(The Business Journal) Aug 2, 2016 - Cure Forward and Personal Genome Diagnostics Inc., a provider of advanced cancer genome testing products and services, today announced an agreement that will enable cancer patients using the Cure Forward Patient Activation platform to select PGDx as their genomic testing service provider.

Transgenomic Launches First Commercially Available CLIA Test for Detection of EGFR C797S Mutations That Predict Resistance to 3rd Generation Kinase Therapies for Lung Cancer

7/25/2016 04:05 pm

(Transgenomic) July 25, 2016 - Transgenomic, Inc. today announced the launch of its new CLIA assays that detect the presence of the EGFR C797S mutation, a novel mechanism of acquired resistance to third-generation tyrosine kinase inhibitor (TKI) drugs for non-small cell lung cancer (NSCLC).

Significant Expansion of Data Available In the Genomic Data Commons

6/30/2016 05:22 pm

(NCI) June 29, 2016 - The recently launched Genomic Data Commons will get a dramatic increase in the power and utility of its resources with the announcement today of the signing of a data sharing agreement between the National Cancer Institute and Foundation Medicine, Inc., a molecular information company that has generated genomic profiles of people with cancer.

New Technique Sorts "Drivers" From "Passengers" in Cancer Genomic Studies, Pinpoints GON4L as New Driver

6/30/2016 05:07 pm

(UCCC/Colorado Cancer Blog) June 29, 2016 - When cancer researchers discover an alteration in a tumor or a line of cancer cells, the alteration may or may not be relevant to the progression of the disease – chances are good (and history has shown) that many alterations that are correlated with cancer are not causative of cancer.

After Negative PET, Drop Bleomycin in Hodgkin's Lymphoma

6/23/2016 10:05 am

(Medscape Medical News) June 22, 2016 - A response-adapted approach to the treatment of patients with advanced Hodgkin's lymphoma de-escalates treatment after an early negative PET scan and intensifies treatment in those with a PET-positive scan — those with the highest risk for treatment failure.

Rosetta Genomics Receives Approval from New York State for HEME FISH-based Assays

6/21/2016 05:13 pm

(Yahoo! Finance) June 21, 2016 - Portfolio of disease-specific diagnostic, prognostic and predictive test panels for various hematologic malignancies now available in all 50 states.

Transgenomic Accelerates Commercialization of ICE COLD-PCR (ICP) amid Plans to Expand Cancer Product Line Ten-Fold

6/14/2016 05:02 pm

(Biotech 365) June 14, 2016 - Transgenomic, Inc., today announced plans to expand its ICE COLD-PCR (ICP)-powered cancer assays ten-fold over the next 18 months, targeting a portfolio of more than 200 exons/mutations expected to be available to partners, cancer researchers, drug developers and clinicians by 2018.

Genomic Health Launches Oncotype SEQ(TM) Liquid Biopsy Mutation Panel

6/14/2016 05:00 pm

(PharmiWeb) June 14, 2016 - Genomic Health, Inc. today announced the commercial launch of Oncotype SEQ™ Liquid Select, the first of several non-invasive liquid biopsy tests that the company plans to deliver through its Oncotype IQ™ Genomic Intelligence Platform.

Newly Launched Genomic Data Commons To Facilitate Data And Clinical Information Sharing

6/7/2016 07:36 pm

(NCI) June 6, 2016 - The Genomic Data Commons (GDC), a unified data system that promotes sharing of genomic and clinical data between researchers, launched today with a visit from Vice President Joe Biden to the operations center at the University of Chicago.

Monday at ASCO: Helping Patients to Help Themselves

6/6/2016 02:00 pm

(Medscape Medical News) June 6, 2016 - News released today at the annual meeting of the American Society of Clinical Oncology shows how lung cancer patients equipped with a smartphone helped themselves to live longer and better.

Genomic Health Announces Multiple Oncotype DX(R) Presentations at ASCO 2016 Showcasing Industry-leading Commitment to Bringing Precision Medicine to Cancer Patients

6/5/2016 11:26 pm

(The Business Journals) June 5, 2016 - Four new analyses of SEER registry provide additional evidence that Oncotype DX accurately predicts patient outcomes in node-negative and node-positive breast cancer and reinforce its value in older women; oral presentation highlights positive impact Oncotype DX has on decision making process, including in node-positive disease.

Immunotherapy Effective Against Some Types of Sarcoma

6/5/2016 06:03 pm

(UPMC) June 5, 2016 - An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute (UPCI). Additional analyses of tumor biopsies and blood samples, which will help the researchers better understand which sarcoma subtypes will benefit most from the new treatment, are underway.

New JTCC Studies Demonstrate Clinical And Economic Value Of Genomic Profiling In Improving Care And Outcomes In Non-Small Cell Lung Cancer And Breast Cancer

6/4/2016 10:15 pm

(The Business Journals) June 4, 2016 - Two new studies co-authored by researchers from John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and discussed at the American Society of Clinical Oncology (ASCO) annual meeting demonstrate the potentially substantial therapeutic benefit of genomic profiling in serious, life-threatening cancers.

Pathway Genomics Provides Updates for CancerIntercept™ Detect Clinical Program

5/26/2016 04:38 pm

(Pathway Genomics) May 26, 2016 - Three clinical investigations now enrolling with the initiation of new study in thyroid cancer detection; two abstracts published in 2016 ASCO annual meeting proceedings.

Transgenomic Unveils the First Rapid Turnaround Liquid Biopsy Metastatic Breast Cancer Panel at AACR 2016 Annual Meeting

4/19/2016 07:18 pm

(TheStreet) Apr 19, 2016 - Transgenomic, Inc., today announced that it is unveiling its new Breast Cancer Analysis Panel this week at the 2016 American Association for Cancer Research (AACR) Annual Meeting.

Agendia’s MammaPrint® First and Only Genomic Assay to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients

4/19/2016 06:20 pm

(Agendia) Apr 18, 2016 - Agendia, Inc., together with the European Organisation for Research and Treatment of Cancer (EORTC) and Breast International Group (BIG), announced results from the initial analysis of the primary objective of the Microarray In Node-negative (and 1 to 3 positive lymph node) Disease may Avoid ChemoTherapy (MINDACT) study at the American Association for Cancer Research Annual Meeting 2016 in New Orleans, LA.

Seven Bridges Cancer Genomics Cloud Hackathon Initiates Innovative Research Projects

4/15/2016 04:24 pm

(VentureBeat) Apr 15, 2016 - Seven Bridges, the biomedical data analysis company, today announced results of the recent hackathon it hosted in collaboration with the National Institutes of Health (NIH) Big Data to Knowledge (BD2K) Initiative, which invited the cancer research community to build portable analysis tools and test drive the National Cancer Institute (NCI) Cancer Genomics Cloud (CGC) pilot.

Increased Travel Burden Associated with Decreased Likelihood of Receiving Radiation Therapy to Treat Rectal Cancer

3/21/2016 11:03 am

(ASTRO) Mar 21, 2016 - Increased travel distance to a cancer treatment facility negatively impacts the likelihood that patients with stage II/III rectal cancer will receive radiation therapy (RT) to treat their disease, according to a new study.

ASCO to Hold Capitol Hill Briefing March 15 on The State of Cancer Care in America: 2016

3/3/2016 11:04 am

(ASCO) Mar 2, 2016 - The State of Cancer Care in America: 2016 report, to be released on March 15 by the American Society of Clinical Oncology (ASCO), chronicles the current realities of the cancer care delivery system in the United States and examines trends in the oncology workforce and practice environment that are affecting patient care and access.

NICE Turns Down Janssen's Imbruvica For CLL

3/2/2016 11:04 am

(PharmaTimes [UK]) Mar 2, 2016 - Patients with chronic lymphocytic leukaemia (CLL) living in England and Wales are unlikely to get access to Janssen UK’s Imbruvica on the NHS after the drug was turned down by cost regulators.

Breast Cancer and Thyroid: Women With Overactive Thyroid Need To Be Extra Cautious

2/12/2016 11:04 am

(International Business Times) Feb 12, 2016 - The study, published in European Journal of Endocrinology, reveals how hyperthyroid women are 11 percent more likely to develop breast cancer, and women with hypothyroidism are 6 percent less likely to develop the cancer.

Sanofi's Combination Diabetes Drug Hits Goal In Late-Stage Trial

7/29/2015 12:01 pm

(Reuters) July 29, 2015 - Sanofi said on Wednesday a first late-stage Phase III study of its LixiLan diabetes drug had met its main target, while another would be completed at the end of the third quarter.

Bavarian Nordic Announces Initiation of NCI-sponsored Phase 2 Study of PROSTVAC in Patients with Localized Prostate Cancer

7/24/2015 11:02 am

(Bavarian Nordic) July 24, 2015 - Bavarian Nordic A/S announced today that the first patient has been enrolled in a new phase 2 clinical study of PROSTVAC, the Company's active prostate cancer immunotherapy candidate.

Novartis Says Lung Cancer Drug Zykadia Gains EU Approval

5/8/2015 06:02 am

(Reuters) May 8, 2015 - Swiss drugmaker Novartis said European health regulators have approved a drug for advanced lung cancer that is intended to treat patients with a specific genetic mutation.

Physical Exercise Helps Women with Breast Cancer to Better Tolerate Chemotherapy

4/28/2015 11:05 am

(Netherlands Cancer Institute [Amsterdam]) Apr 28, 2015 - Women with breast cancer who follow a physical exercise program during their chemotherapy treatment experience less side effects like fatigue, reduced physical fitness, nausea and pain.

House Passes Boehner-Pelosi Medicare Deal in Resounding Vote

3/26/2015 12:04 pm

(The Hill) Mar 26, 2015 - The House on Thursday overwhelmingly voted to repeal automatic cuts to doctors under Medicare, endorsing a rare bipartisan deal that Speaker John Boehner (R-Ohio) negotiated with Democrats.

Anthem, Cigna to Help Obama Add Value to U.S. Medical Billing

3/25/2015 12:03 pm

(Bloomberg) Mar 25, 2015 - President Barack Obama is enlisting private companies into his drive to change the way the U.S. pays its medical bills, including insurers Anthem Inc. and Cigna Inc. and casino chain Caesars Entertainment Corp.

$10 Copy of Gilead Blockbuster Sovaldi Appears in Bangladesh

3/9/2015 12:00 pm

(Bloomberg) Mar 8, 2015 - A $10 version of Sovaldi, the Gilead Sciences Inc. hepatitis C treatment that sells for $1,000 a pill in the U.S., is now available in Bangladesh and could make its way to other parts of the world where the U.S. company doesn’t have patents.

Tolero Pharmaceuticals Receives EMA Orphan Drug Designation For Alvocidib For the Treatment of Acute Myeloid Leukemia

2/26/2015 12:01 pm

(The Business Journals) Feb 25, 2015 - Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for alvocidib for the treatment of patients with acute myeloid leukemia (AML).

Raleigh Drug Co. to Relaunch Cancer Pain Medication; Shares Bounce

1/28/2015 12:01 pm

(Triangle Business Journal) Jan 27, 2015 - BioDelivery will re-launch breakthrough cancer pain medicine Onsolis in the United States and find a new partner for the drug, ideally returning more revenue.

Express Scripts Sees Opportunity to Lower Cancer Treatment Cost

1/14/2015 07:00 am

(Reuters) Jan 13, 2015 - Express Scripts, the largest U.S. pharmacy benefit manager, on Tuesday said cost savings on expensive cancer treatments could be achieved if the company were involved earlier in the decision-making process.

Pharma and Docs Up in Arms Over Cancer Drugs Fund Cuts

1/8/2015 07:00 am

(PharmaTimes [UK]) Jan 8, 2015 - The list of drugs to be cut from the Cancer Drugs Fund has yet to be confirmed but drugmakers and doctors have already gone public with their criticisms.

Treatment For Relapsed Multiple Myeloma Patients Guided by FoundationOne® Heme Results in Promising Clinical Activity

12/8/2014 05:03 pm

(TheStreet) Dec 8, 2014 – Foundation Medicine, Inc. today announced new data demonstrating that its comprehensive genomic profile, FoundationOne® Heme, identified genomic alterations in patients with heavily pre-treated multiple myeloma that informed treatment with trametinib, an FDA-approved targeted therapeutic agent.

HPV Vaccine Uptake Among Girls is Lowest in States With Highest Rates of Cervical Cancer

11/12/2014 06:00 am

(AACR) Nov 11, 2014 - The proportion of adolescent girls receiving human papillomavirus (HPV) vaccines was much lower in states with higher rates of cervical cancer incidence and mortality, according to new data.

Rutgers Receives $10 Million Donation for Cancer Research

9/9/2014 07:02 am

(NJ.com) Sept 9, 2014 - Rutgers University has received a $10 million anonymous grant to help its scientists discover targeted therapies for hard-to-treat cancers.

Novartis Hands Over Experimental TB Drugs in Antibiotic Pullback

8/20/2014 07:02 am

(Reuters) Aug 20, 2014 - Novartis has signed a licensing deal to hand over its experimental tuberculosis (TB) drugs to the Global Alliance for TB Drug Development, joining a growing Big Pharma retreat from antibiotics.

CMS Fixes Tech Glitch That Hobbled Pharma Payment Disclosures

8/15/2014 07:04 am

(Wall Street Journal/Pharmalot blog) Aug 14, 2014 - The federal government is back online with a website where U.S. doctors and teaching hospitals can review information about payments they have received from drug and device makers, about 11 days after a government agency shut it down to investigate a data mix-up.

Genomic Health Announces Positive Topline Results of Additional, Large Independent Validation Study of Oncotype DX(R) Prostate Cancer Test with Multiple Clinical Endpoints

8/6/2014 07:00 am

(Genomic Health) Aug 6, 2014 - Genomic Health, Inc. today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer.

Sanofi Cholesterol Drug Meets Main Goal of 9 Trials

7/30/2014 07:01 am

(BloombergBusinessWeek) July 30, 2014 - Sanofi and Regeneron Pharmaceuticals Inc.’s cholesterol drug cut levels of the artery-clogging protein in nine trials, and reduced the rate of heart attack, stroke and death in one test, as the companies race with Amgen Inc. to get a new treatment to market.